Key Details
Price
$89.41Last Dividend
$0.44Annual Revenue
$5.59 BAnnual EPS
$4.02Annual ROE
7.60%Beta
0.54Events Calendar
Next earnings date:
Jan 23, 2025Recent quarterly earnings:
Oct 30, 2024Recent annual earnings:
Jan 23, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Dec 31, 2024Next split:
N/ARecent split:
Sept 12, 2014Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Axis Capital (AXS) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.
Axsome Therapeutics is experiencing significant revenue growth from its products Auvelity and Sunosi, and it has exciting late-stage drugs in development for migraine, fibromyalgia, and narcolepsy. Key upcoming milestones include AXS-07 for migraines, which is set for review on January 31, 2025, as well as AXS-12 for narcolepsy and AXS-14 for fibromyalgia. Although the Phase 3 results for AXS-05 in treating agitation in Alzheimer's were mixed, the overall data remains positive, leading to an optimistic outlook.
The ACCORD-2 Phase 3 trial for agitation in Alzheimer's disease has successfully met its main goal when compared to a placebo, with a significant result (p=0.001) regarding the time until relapse.
The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons to make the most of this tool.
Even with increased losses from disasters, MCY, AXS, and PLMR are doing better than the industry average and significantly outperforming the Zacks S&P 500 and the Finance sector.
AXIS Capital is a top company in specialty insurance and reinsurance, showing a 30.2% annual growth in NOPAT and a 15.3% return on invested capital over the last twelve months. With a varied portfolio, careful risk management, and a focus on innovation, the company is well-equipped to provide value even in tough market conditions. The current market valuation suggests a 31% drop in future NOPAT, making it an attractive investment option based on its solid past performance.
No matter if you focus on value, growth, or momentum investing, discovering solid stocks is simpler with the Zacks Style Scores, which is a key part of the Zacks Premium research service.
No matter if you invest in value, growth, or momentum, discovering solid stocks is simpler with the Zacks Style Scores, which is a key aspect of the Zacks Premium research service.
At Zacks, we concentrate on the reliable Zacks Rank system, which highlights earnings estimates and changes in those estimates to identify excellent stocks. However, we also keep an eye on the most recent trends in value, growth, and momentum to support our top selections.
This is a comparison of how Axis Capital (AXS) and Mr. Cooper (COOP) have done in relation to their industry this year.
FAQ
- What is the primary business of AXIS Capital Holdings Limited?
- What is the ticker symbol for AXIS Capital Holdings Limited?
- Does AXIS Capital Holdings Limited pay dividends?
- What sector is AXIS Capital Holdings Limited in?
- What industry is AXIS Capital Holdings Limited in?
- What country is AXIS Capital Holdings Limited based in?
- When did AXIS Capital Holdings Limited go public?
- Is AXIS Capital Holdings Limited in the S&P 500?
- Is AXIS Capital Holdings Limited in the NASDAQ 100?
- Is AXIS Capital Holdings Limited in the Dow Jones?
- When was AXIS Capital Holdings Limited's last earnings report?
- When does AXIS Capital Holdings Limited report earnings?
- Should I buy AXIS Capital Holdings Limited stock now?